Sort   by:  
 Page size 
UnknownPhase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
Not available
S-EPMC3157979 | biostudies-literature
UnknownThree-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial.
Not available
S-EPMC6286164 | biostudies-literature
UnknownCirculating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.
Not available
S-EPMC4209100 | biostudies-literature
UnknownSWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
Not available
S-EPMC4268253 | biostudies-literature
UnknownCorrelative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Not available
S-EPMC5070556 | biostudies-literature
UnknownAdjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Not available
S-EPMC4175521 | biostudies-literature
UnknownTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Not available
S-EPMC6193457 | biostudies-literature
UnknownAdjuvant ovarian suppression in premenopausal breast cancer.
Not available
S-EPMC4341825 | biostudies-literature
Sort   by:  
 Page size